By Lewis Krauskopf NEW YORK (Reuters) -Woes for U.S. healthcare stocks have worsened this year driven partly by Trump ...

Emma Charles shares her vision for healthcare, how AI is reshaping pharma and why access to innovation must be faster and ...

Key Points On July 22, 2025, the U.S. Food and Drug Administration issued a Complete Response Letter for RP1, delaying potential commercialization and revenue. Research and development expenses ...

Detailed price information for Prime Medicine Inc (PRME-Q) from The Globe and Mail including charting and trades.

Patients with inflammatory bowel disease (IBD) have a 48% greater relative risk of developing interstitial lung disease (ILD) ...

Key Points GAAP revenue surged to $66.8 million in Q2 2025, driven by recognition of one-time license and milestone payments, exceeding analyst estimates by 3,065.9% (GAAP). GAAP loss per share ...

On January 16, 2025, Avacta reported encouraging results from its Phase I trial of AVA6000. In patients with salivary gland ...

Meanwhile, mRNA vaccine maker Moderna is cutting around 500 jobs (10% of its workforce) as part of a commitment to save $1.5 ...

Flaws remain for office in the San Francisco Peninsula office — but demand is starting to improve, as net absorption was -406 ...

Covenant Health is now offering CAR T-cell therapy at the Joe Arrington Cancer Research & Treatment Center, marking a major ...

Bristol-Myers Squibb recently saw a 6.39% drop in its stock value, with weak momentum and bearish signals from technical ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...